While mainstream evidence suggests that ER+/PR+ BC patients generally exhibit a favorable prognosis than ER+/PR− cases, the role of PR in predicting outcomes remains complex and inconsistently predictive.45 The gene discussed is ESR1; the disease is breast cancer.